Skip to main content
Premium Trial:

Request an Annual Quote

Decode Reports Decreased Q3 Revenues

NEW YORK, Nov. 14 - Decode Genetics today reported decreased revenue for the third quarter of 2002.

 

The company said its total revenue was $9 million in the third quarter which ended September 30, compared to $9.7 million in the same quarter of 2001.

 

Decode reported a net loss of $85.7 million, or $1.61 per share, in the third quarter 2002 compared to a net loss of $8.9 million, or $.20 per share, in the year-ago period. The company said the increased loss reflected in part a substantial one-time milestone revenue received in the year-ago period. Additionally, in the current third quarter Decode recorded impairment, employee termination benefits, and other charges of $64.8 million as a result of the acquisition of MediChem Life Sciences in March.

 

R&D spending increased to $23.5 million compared to $16.8 million in the same period a year ago.

 

Decode also reported $104.9 million in cash and cash equivalents, including $6 million in restricted cash, at the end of September 2002.

 

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.